Anthropic expanded the operational scope of its Claude artificial intelligence models across biotechnology and clinical drug development, applying the system to projects targeting cancer, food allergies, and rare muscular disorders through partnerships with several life sciences firms, according to a report by TechRadar.
Generate Biomedicines Modifies CAR-T Cell Components Using Claude Code
At Generate Biomedicines, researchers utilized Claude Code to modify a key component of chimeric antigen receptor (CAR-T) cell therapy, a treatment approach traditionally used against blood cancers. The team aimed to create additional space for genetic instructions designed to help the therapy target solid tumors.
The redesigned component was roughly 70 percent shorter than its original counterpart. Laboratory experiments demonstrated that immune cells produced about 10 times more receptors following the modification. According to reported findings, the altered cells destroyed cancer cells more effectively and maintained activity for longer periods.
Divergence Labs Designs 35,000 Antibody Candidates for Food Allergy Treatment
Divergence Labs deployed Claude to design antibody candidates for a potential food allergy treatment directed against the IgE immune molecule. Over a one-month period, the system generated approximately 35,000 molecular designs, including candidates that satisfied two separate functions required for the proposed therapy.
Initial laboratory tests identified 3 designs capable of binding to IgE and 20 additional designs capable of detaching IgE from immune cells. Among those 20, three designs appeared more effective than the reference drug at clearing IgE from immune cells.
Over a 10-week span, researchers produced and evaluated roughly 1,010 variants, measuring binding capacity, stability, and unwanted molecular aggregation.
The cancer-targeting version that achieved the top performance bound to its target more than 10 times more strongly than the initial version and remained stable at temperatures 18°C higher than those supported by the initial version. The second fragment, designed for longer-lasting drug action, aggregated more than 100 times slower than its initial version.
Enveda Reduces Manual Document Verification Time by 89 Percent
Enveda used Claude to review manufacturing documents, a task that could represent up to 75 percent of working hours for certain chemists. During an evaluation of 1,061 pages, the system identified all 11 issues previously found by human reviewers, alongside seven additional issues.
The automated review method reduced manual verification time by 89 percent, shortening the review duration from more than 25 hours to under three hours.
Bristol Myers Squibb Evaluates Clinical Trial Plans with Claude
Anthropic also established a partnership with Bristol Myers Squibb to assess clinical trial designs and estimate their probability of success. Michael Pourdehnad, senior vice president of early clinical development at Bristol Myers Squibb, stated that Claude produced a robust initial analysis from a single prompt.
Pourdehnad noted that the analysis assisted in evaluating development options that otherwise would have required several days of work. Both companies intend to expand their collaboration to examine how Claude can contribute to early clinical development decisions.
Anthropic stated that direct collaboration with drug developers assists the company in identifying model weaknesses and opportunities for improvement across scientific research domains.
Worth a look
